Central neuroaxis blockade and coronary circulation

N Rolf1

  • 1Klinik und Poliklinik für Anaesthesiologie und operative Intensivmedizin, Westfälische Wilhelms-Universität Münster, Albert Schweitzer-Strasse 33, D-48149 Münster, Germany.

Insights

Thoracic epidural anesthesia benefits heart function by blocking sympathetic nerves, while lumbar epidural anesthesia may harm heart areas with blocked arteries.

Area of Science:

  • Cardiovascular Physiology
  • Autonomic Nervous System Regulation
  • Anesthesiology

Background:

  • Coronary circulation is modulated by the autonomic nervous system.
  • Sympathetic stimulation causes vasodilation in healthy coronary arteries but vasoconstriction in stenotic arteries.
  • This differential response impacts myocardial perfusion and function.

Purpose of the Study:

  • To investigate the effects of thoracic epidural anesthesia (TEA) and lumbar epidural anesthesia (LEA) on coronary circulation and myocardial function.
  • To understand the role of sympathetic nervous system modulation in coronary perfusion.
  • To evaluate the clinical implications of different epidural anesthesia techniques in patients with coronary artery disease.

Main Methods:

  • Review of experimental studies and clinical evidence.
  • Analysis of the impact of sympathetic stimulation on healthy and stenotic coronary arteries.
  • Comparison of the effects of thoracic versus lumbar epidural anesthesia on cardiac sympathetic outflow.

Main Results:

  • Thoracic epidural anesthesia demonstrates beneficial effects on coronary perfusion and myocardial function in both normal and ischemic myocardium.
  • Segmental lumbar epidural anesthesia can lead to a compensatory increase in cardiac sympathetic outflow.
  • This increase in sympathetic drive may compromise myocardial areas supplied by stenotic coronary arteries.

Conclusions:

  • Blockade of cardiac sympathetic drive via thoracic epidural anesthesia is beneficial for coronary perfusion and myocardial function.
  • Lumbar epidural anesthesia's potential to increase cardiac sympathetic outflow poses risks to patients with stenotic coronary arteries.
  • These findings highlight the importance of anesthetic technique selection in managing patients with compromised coronary circulation.

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Neural Regulation of Blood Pressure01:18

Neural Regulation of Blood Pressure

The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups: